πŸ‡ΊπŸ‡Έ FDA
Patent

US 10350265

Therapeutic applications of Smad7

granted A61KA61K31/7088A61K38/00

Quick answer

US patent 10350265 (Therapeutic applications of Smad7) held by The Regents of the University of Colorado, a Body Corporate expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Jul 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/7088, A61K38/00, A61K38/162, A61K38/1709